Roche announced positive results from the randomised phase II GO29365 study
Roche announced positive results from a randomised phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus MabThera®/Rituxan (rituximab) against BR alone in people with relapsed or refractory DLBCL who are not candidates for haematopoietic stem cell transplant. December 10, 2017